Health
First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC – News-Medical.Net
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprisin…
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation.
The Oncota…
-
Noosa News23 hours agoDuo revealed as new hosts for 4BC Breakfast
-
Noosa News19 hours agoMan arrested after mother and 10-year-old girl killed in car crash in Far North Queensland’s Doomadgee
-
General16 hours agoFormer Neighbours star Damien Richardson found guilty of public Nazi salute
-
Noosa News19 hours agoFraser Bax | Thynne + Macartney – Proctor